Biohaven
BHVN · NYSE
Bulios Fair Price
$7.62
44.0% downside
Current Price
$13.61
According to Bulios Fair Price, BHVN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) is a biotechnology company focused on researching, developing, and commercializing therapeutic products for the treatment of neurological and psychiatric disorders. The company aims to discover novel drug candidates and innovative therapies for patients suffering from migraine, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other neurological disorders. Biohaven is advancing and testing drugs in various stages of clinical trials and aspires to bring new therapeutic solutions to the field of neurological treatment. The company collaborates with academic and industry partners and focuses on innovation in the field of neuroscience. Biohaven Pharmaceutical Holding Company Ltd. (BHVN) shares may present an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with promising neurological treatment innovations and a strong commitment to addressing neurological disorders.
Sector
Healthcare
Industry
Biotechnology
CEO
Vladimir Coric
Employees
274
Headquarters
New Haven
Upcoming events
Earnings
Upcoming earnings report